We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Tempus AI's Data Business Is Expanding and Adding to Revenues: Here's How
Read MoreHide Full Article
Key Takeaways
Data and Services revenues for TEM rose 26.1% as Insights bookings hit $150 million.
Tempus AI expanded capabilities with the Paige acquisition and a deeper Northwestern Medicine partnership.
TEM broadened Tempus Next into breast cancer, adding real-time insights to support guideline-based care.
Tempus AI’s (TEM - Free Report) third-quarter 2025 results highlight the growing strategic importance of its Insights and Data & Services business, which is emerging as a high-margin and scalable revenue stream beyond traditional genomic testing. Data and Services revenues totaled $81.3 million, up 26.1% year over year, driven primarily by Insights (data licensing).
Insights bookings reached $150 million across multiple new contracts, reflecting 37.6% year-over-year revenue growth, building on the multi-hundred-million-dollar foundation model deal signed earlier this year. This momentum underscores how Tempus is monetizing its large multimodal dataset spanning genomic, clinical, imaging, and digital pathology information alongside AI-powered insights and algorithms.
The company further strengthened its data and AI capabilities through the acquisition of Paige, an AI leader in digital pathology, enhancing its dataset, technical expertise and footprint in this emerging field. It also expanded its collaboration with Northwestern Medicine to integrate David, Tempus’ generative AI clinical co-pilot, into the EHR platform to streamline and transform clinical workflows. Additionally, Tempus Next expanded into breast cancer, offering real-time insights to help clinicians close guideline-based care gaps, underscoring continued innovation across the Data and Services segment.
While long-term success hinges on retention, contract expansion, and broader adoption of AI-driven tools in clinical workflows, the trajectory suggests that the company is evolving from a testing-focused diagnostics company into a differentiated data-driven precision medicine platform with expanding recurring revenue potential.
Peer Update
SOPHiA GENETICS (SOPH - Free Report) continued to scale its data platform, with usage increasing both through higher activity from existing customers and strong new customer additions. SOPH performed a record 99,000 analyses on its SOPHiA DDM platform, marking 9% year-over-year volume growth. Growth momentum was further supported by the onboarding of 31 new customers in the quarter. During the quarter, SOPHiA GENETICS also launched SOPHiA DDM Digital Twins, an AI-driven research technology designed to simulate patient-specific treatment outcomes and support more precise clinical decision-making.
ICON’s (ICLR - Free Report) digital innovation strategy plays a key role in enhancing clinical delivery by integrating AI and key technology advancements into clinical research. In line with this, ICLR introduced two new AI-enabled tools, iSubmit and SmartDraft. iSubmit automates the clinical trial document management process primarily through managing electronic trial master files. SmartDraft streamlines the clinical contract drafting process during study startup, allowing sites to shorten overall startup times.
TEM’s Stock Price Performance
In the past year, Tempus shares have rallied 10% against the industry’s 4.1% decline. The S&P 500 composite has improved 12.3% in the same time.
Image Source: Zacks Investment Research
Expensive Valuation
TEM currently trades at a forward 12-month Price-to-Sales (P/S) of 8.18X compared with the industry average of 5.81X.
Image Source: Zacks Investment Research
TEM Stock Estimate Trend
In the past 30 days, Tempus AI's loss per share estimate for 2025 has narrowed 3 cents.
Image: Bigstock
Tempus AI's Data Business Is Expanding and Adding to Revenues: Here's How
Key Takeaways
Tempus AI’s (TEM - Free Report) third-quarter 2025 results highlight the growing strategic importance of its Insights and Data & Services business, which is emerging as a high-margin and scalable revenue stream beyond traditional genomic testing. Data and Services revenues totaled $81.3 million, up 26.1% year over year, driven primarily by Insights (data licensing).
Insights bookings reached $150 million across multiple new contracts, reflecting 37.6% year-over-year revenue growth, building on the multi-hundred-million-dollar foundation model deal signed earlier this year. This momentum underscores how Tempus is monetizing its large multimodal dataset spanning genomic, clinical, imaging, and digital pathology information alongside AI-powered insights and algorithms.
The company further strengthened its data and AI capabilities through the acquisition of Paige, an AI leader in digital pathology, enhancing its dataset, technical expertise and footprint in this emerging field. It also expanded its collaboration with Northwestern Medicine to integrate David, Tempus’ generative AI clinical co-pilot, into the EHR platform to streamline and transform clinical workflows. Additionally, Tempus Next expanded into breast cancer, offering real-time insights to help clinicians close guideline-based care gaps, underscoring continued innovation across the Data and Services segment.
While long-term success hinges on retention, contract expansion, and broader adoption of AI-driven tools in clinical workflows, the trajectory suggests that the company is evolving from a testing-focused diagnostics company into a differentiated data-driven precision medicine platform with expanding recurring revenue potential.
Peer Update
SOPHiA GENETICS (SOPH - Free Report) continued to scale its data platform, with usage increasing both through higher activity from existing customers and strong new customer additions. SOPH performed a record 99,000 analyses on its SOPHiA DDM platform, marking 9% year-over-year volume growth. Growth momentum was further supported by the onboarding of 31 new customers in the quarter. During the quarter, SOPHiA GENETICS also launched SOPHiA DDM Digital Twins, an AI-driven research technology designed to simulate patient-specific treatment outcomes and support more precise clinical decision-making.
ICON’s (ICLR - Free Report) digital innovation strategy plays a key role in enhancing clinical delivery by integrating AI and key technology advancements into clinical research. In line with this, ICLR introduced two new AI-enabled tools, iSubmit and SmartDraft. iSubmit automates the clinical trial document management process primarily through managing electronic trial master files. SmartDraft streamlines the clinical contract drafting process during study startup, allowing sites to shorten overall startup times.
TEM’s Stock Price Performance
In the past year, Tempus shares have rallied 10% against the industry’s 4.1% decline. The S&P 500 composite has improved 12.3% in the same time.
Image Source: Zacks Investment Research
Expensive Valuation
TEM currently trades at a forward 12-month Price-to-Sales (P/S) of 8.18X compared with the industry average of 5.81X.
Image Source: Zacks Investment Research
TEM Stock Estimate Trend
In the past 30 days, Tempus AI's loss per share estimate for 2025 has narrowed 3 cents.
Image Source: Zacks Investment Research
TEM stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.